The cost-effectiveness of typhoid Vi vaccination programs: Calculations for four urban sites in four Asian countries

Vaccine

Volumn 26, Issue 50, 2008, Pages 6305-6316

  Cook, Joseph ^a   Jeuland, Marc ^b   Whittington, Dale ^b,c   Poulos, Christine ^d   Clemens, John ^e   Sur, Dipika ^f   Anh, Dang Duc ^g   Agtini, Magdarina ^h   Bhutta, Zulfiqar ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d RTI INTERNATIONAL   (United States)

^e International Vaccine Institute   (South Korea)

^f NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^g NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^h NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

ⁱ AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Asia; Cost effectiveness; Typhoid vaccination

Indexed keywords

TYPHOID VACCINE;

ADOLESCENT; ARTICLE; ASIA; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TYPHOID FEVER; URBAN AREA; VACCINATION;

ADOLESCENT; ADULT; ASIA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INDIA; INDONESIA; PAKISTAN; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; URBAN POPULATION; VACCINATION; VIETNAM; YOUNG ADULT;

EID: 55749097062     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.040     Document Type: Article

References (38)

1. Parry C.M., Hien T.T., Dougan G., White N.J., and Farrar J.J. Typhoid fever. N Engl J Med 347 22 (2002) 1770-1782
2. Crump J.A., Luby S.P., and Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 82 5 (2004) 346-353
3. Ochiai R.L., Acosta C.J., Danovaro-Holliday M.C., Dong B., Bhattacharya S.K., Agtini M., et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull WHO 86 (2008) 260-268
4. Griffin G.E. Typhoid fever and childhood vaccine strategies (Commentary). Lancet 354 9180 (1998) 698
5. Bahl R., Sinha A., Poulos C., Whittington D., Sazawal S., Kumar R., et al. Costs-of-illness of typhoid fever in Indian urban slum community: implications for vaccination policy. J Health Popul Nutr 22 3 (2004) 304-310
6. Hessel L., Debois H., Fletcher M., and Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 18 (1999) 609-620
7. Yang H.H., Kilgore P.E., Yang L.H., Park J.-K., Pan Y.-F., Kim Y., et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 183 (2001) 1775-1780
8. Yang H.H., Wu C.G., Wie G.Z., Gu Q.W., Wang B.R., Wang L.Y., et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull WHO 79 7 (2001) 625-631
9. Acosta C., Galindo C., Deen J., Ochiai R., Lee H., von Seidlein L., et al. Vaccines against cholera, typhoid fever and shigellosis for developing countries. Expert Opin Biol Ther 12 (2004) 1939-1951
10. Acharya I., Lowe C., Thapa R., Gurubacharya V., Shrestha M., Cadoz M., et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 317 (1987) 1101-1104
11. Canh D.G., Lin F.K., Thiem V.D., Trach D.D., Trong N.D., Mao N.D., et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year old Vietnamese children. N Engl J Med 72 11 (2004) 6586-6588
12. Szu S.C., Taylor D.N., and Trofa A.C. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 4440-4444
13. Papadimitropoulos V., Vergidis P.I., Blitziotis I., and Falagas M.E. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 10 8 (2004) 681-683
14. Poulos C., Bahl R., Whittington D., Bhan M.K., Clemens J.D., and Acosta C.J. A cost-benefit analysis of typhoid fever immunization programs in an Indian urban slum community. J Health Popul Nutr 22 3 (2004) 311-321
15. Canh D.G., Whittington D., Thoa L.T.K., Utomo N., Hoa N.T., Poulos C., et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plann (2006) 241-255
16. In: Jamison D.T., Breman J.G., Measham A., Alleyne G., Claeson M., Evans D.B., et al. (Eds). Disease control priorities in developing countries. 2nd. ed (2006), The World Bank and Oxford University Press, Washington, DC
17. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis (2003), World Health Organization, Geneva, Switzerland
18. Musgrove P., and Fox-Rushby J. Cost-effectiveness analysis for priority setting. In: Jamison D.T., Breman J.G., Measham A.R., Alleyne G., Claeson M., Evans D.B., et al. (Eds). Disease control priorities in developing countries. 2nd ed. (2006), The World Bank, Washington, DC
19. World Bank. Investing in Health. World Development Report. Washington, DC: World Bank; 1993.
20. International Monetary Fund. World Economic Outlook database. Available from: www.imf.org/external/ns/cs.asox?id=28 [accessed April 2007].
21. World Health Organization. Typhoid fever. http://www.who.int/topics/typhoid_fever/en/; 2007.
22. World Health Organization. Typhoid fever, Democratic Republic of Congo - update. Wkly Epidemiol Rec 80 (2005) 30-31
23. UNESCO. http://stats.uis.unesco.org; 2008.
24. Poulos C, Riewpaiboon A, Stewart JF, Nyamete A, Guh S, Clemens J, et al. Cost of illness due to typhoid fever in five Asian countries; October, manuscript in preparation.
25. Whittington D, Sur D, Cook J, Chatterjee S, Masker B, Lahore M, et al. Private demand for cholera and typhoid vaccines in Kolkata, India. World Dev, forthcoming.
26. Cook J., Whittington D., Canh D.G., Johnson F.R., and Nyamete A. The reliability of stated preferences for cholera and typhoid vaccines with time to think in Hue, Vietnam. Econ In 45 1 (2007) 100-114
27. Kim D., Canh D.G., Poulos C., Thoa L.T.K., Cook J., Hoa N.T., et al. Private demand for cholera vaccines in Hue, Vietnam. Value Health 11 1 (2008) 119-128
28. Lucas M., Jeuland M., Deen J., Lazaro N., MacMahon M., Nyamete A., et al. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 25 14 (2007) 2599-2609
29. Islam Z., Maskery B., Nyamete A., Horowitz M., Yunus M., and Whittington D. Private demand for cholera vaccines in rural Matlab. Bangladesh Health Policy 85 2 (2008) 184-195
30. Lauria D, Stewart J. Vaccination Costs: Working paper, UNC Environ Sci Eng; July 2007.
31. Sinha A., Levine O., Knoll M.D., Muhib F., and Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369 (2007) 389-395
32. In: Murray C., and Lopez A.D. (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996), Harvard University Press, Cambridge, MA
33. Lin F.-Y.C., Ho V.A., Bay P.V., Thuy N.T.T., Bryla D., Thanh T.C., et al. The epidemiology of typhoid fever in the Dong Thap province. Mekong Delta Region of Vietnam. Am J Trop Med Hyg 62 5 (2000) 644-648
34. Laxminarayan R., Mills A.J., Breman J.G., Measham A.R., Alleyne G., Claeson M., et al. Advancement of global health: key messages from the Diseases Control Priorities Project. Lancet 367 (2006) 1193-1208
35. International Institute for Population Statistics. 2005-2006 National Family Health Survey (NFS-3): Fact Sheet for West Bengal. International Institute for Population Sciences. www.nfhsindia.org/pdf/WB.pdf; 2008.
36. Ministry of Health and Family Welfare. National Health Accounts 2001-2002. New Delhi: India Ministry of Health and Family Welfare; December 2005. http://mohfw.nic.in.
37. Global Alliance for Vaccines and Immunization (GAVI). Guidelines for preparing proposals for GAVI/Vaccine Fund Investment: GAVI; May 2004. http://www.gavialliance.org/support/how/guidelines/index.php.
38. Lauria DT, Masker B, Poulos C, Whittington D. An optimization model for use of the Vi polysaccharide vaccine to prevent typhoid in developing countries; 2008. Mimeo: University of North Carolina at Chapel Hill.